Mesothelioma tumor cells modulate dendritic cell lipid content, phenotype and function

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Gardner, Joanne K ^a   Mamotte, Cyril D S ^a   Patel, Priya ^a   Yeoh, Teong Ling ^a   Jackaman, Connie ^a   Nelson, Delia J ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; INTERLEUKIN 10; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CD4+ CD8ALPHA- DENDRITIC CELL; CD4- CD8ALPHA- DENDRITIC CELL; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; LYMPHOCYTE PROLIFERATION; MALE; MESOTHELIOMA; MESOTHELIOMA CELL LINE; MONOCYTE DERIVED DENDRITIC CELL; MOUSE; NONHUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; UPREGULATION; ANIMAL; C57BL MOUSE; IMMUNOLOGY; IMMUNOPHENOTYPING; LIPID METABOLISM; METABOLISM; MIXED LYMPHOCYTE CULTURE; PATHOLOGY; TUMOR CELL LINE;

MURINAE;

ANIMALS; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOPHENOTYPING; LIPID METABOLISM; LYMPHOCYTE CULTURE TEST, MIXED; MESOTHELIOMA; MICE; MICE, INBRED C57BL;

EID: 84928905606     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123563     Document Type: Article

References (49)

1. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004; 4: 941-952. PMID: 15573129
2. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000; 6: 1755-1766. PMID: 10815894
3. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996; 2: 1096-1103. PMID: 8837607
4. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-KB activation in hemopoietic progenitor cells. J Immunol. 1998; 160: 1224-1232. PMID: 9570538
5. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta-1 and interleukin-10. Blood. 2001; 98: 2992-2998. PMID: 11698282
6. Diao J, Zhao J, Winter E, Cattral MS. Tumors suppress in situ proliferation of cytotoxic T cells by promoting differentiation of Gr-1+ conventional dendritic cells through IL-6. J Immunol. 2011; 186: 5058-5067. doi: 10.4049/jimmunol.1004125 PMID: 21430223
7. Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res. 2003; 63: 2150-2157. PMID: 12727833
8. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L, et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol. 1998; 28: 359-369. PMID: 9485215
9. Sombroek CC, Stam AGM, Masterson AJ, Lougheed SM, Schakel MJAG, Meijer C, et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol. 2002; 168: 4333-4343. PMID: 11970975
10. Caldwell S, Heitger A, Shen W, Liu Y, Taylor B, Ladisch S. Mechanisms of ganglioside inhibition of APC function. J Immunol. 2003; 171: 1676-1683. PMID: 12902465
11. Villablanca EJ, Raccosta L, Zhou D, Fontana R, Maggioni D, Negro A, et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med. 2010; 16: 98-105. doi: 10.1038/nm.2074 PMID: 20037595
12. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010; 16: 880-886. doi: 10.1038/nm.2172 PMID: 20622859
13. Robinson BWS, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005; 366: 397-408. PMID: 16054941
14. Manning LS, Whitaker D, Murch AR, Garlepp MJ, Davis MR, Musk AW, et al. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer. 1991; 47: 285-290. PMID: 1703129
15. Ke Y, Reddel RR, Gerwin BI, Reddel HK, Somers AN, McMenamin MG, et al. Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol. 1989; 134: 979-991. PMID: 2541616
16. Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, et al. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: A novel mechanism for IL-2. J Immunol. 2003; 171: 5051-5063. PMID: 14607902
17. Sixt M, Kanazawa N, Selg M, Samson T, Roos G, Reinhardt DP, et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity. 2005; 22: 19-29. PMID: 15664156
18. Parish CR. Fluorescent dyes for lymphocyte migration and proliferation studies. Immunol Cell Biol. 1999; 77: 499-508. PMID: 10571670
19. Mamotte CDS, Sturm M, Foo JI, van Bockxmeer FM, Taylor RR. Familial defective apolipoprotein B-100 (FDB): Effect of simvastatin therapy on LDL-receptor binding. Atherosclerosis. 1996; 125: 103-110. PMID: 8831932
20. Lutz MB, Kukutsch N, Ogilvie ALJ, Robner S, Koch F, Romani N, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999; 223: 77-92. PMID: 10037236
21. Cao X, Sugita M, van der Wel N, Lai J, Rogers RA, Peters PJ, et al. CD1 molecules efficiently present antigen in immature dendritic cells and traffic independently of MHC class II during dendritic cell maturation. J Immunol. 2002; 169: 4770-4777. PMID: 12391186
22. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol. 2002; 2: 151-161. PMID: 11913066
23. Pooley JL, Heath WR, Shortman K. Intravenous soluble antigen is presented to CD4 T cells by CD8-dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol. 2001; 166: 5327-5330. PMID: 11313367
24. Nakano H, Yanagita M, Gunn MD. CD11c+B220+Gr-1+ cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med. 2001; 194: 1171-1178. PMID: 11602645
25. Gottfried E, Kreutz M, Mackensen A. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev. 2008; 19: 65-77. PMID: 18061513
26. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol. 2003; 170: 3488-3494. PMID: 12646609
27. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annual Rev Immunol. 2000; 18: 767-811. PMID: 10837075
28. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol. 2000; 164: 1269-1276. PMID: 10640740
29. Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer. 2003; 89: 1463-1472. PMID: 14562018
30. Gerner MY, Mescher MF. Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells. J Immunol. 2009; 182: 2726-2737. doi: 10.4049/jimmunol.0803479 PMID: 19234167
31. Coventry B, Heinzel S. CD1a in human cancers: A new role for an old molecule. Trends Immunol. 2004; 25: 242-248. PMID: 15099564
32. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol. 2004; 165: 1853-1863. PMID: 15579430
33. Coventry BJ, Morton J. CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer. Br J Cancer. 2003; 89: 533-538. PMID: 12888826
34. Goldman SA, Baker E, Weyant RJ, Clarke MR, Myers JN, Lotze MT. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg. 1998; 124: 641-646. PMID: 9639473
35. Gogolak P, Rethi B, Szatmari I, Lanyi A, Dezso B, Nagy L, et al. Differentiation of CD1a- and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPAR-gamma. Blood. 2007; 109: 643-652. PMID: 16968896
36. Zeyda M, Saemann MD, Stuhlmeier KM, Mascher DG, Nowotny PN, Zlabinger GJ, et al. Polyunsaturated fatty acids block dendritic cell activation and function independently of NF-KB activation. J Biol Chem. 2005; 280: 14293-14301. PMID: 15684433
37. Le Naour F, Hohenkirk L, Grolleau A, Misek DE, Lescure P, Geiger JD, et al. Profiling changes in gene expression during differentiation and maturation of monocyte-derived dendritic cells using both oligonucleotide microarrays and proteomics. J Biol Chem. 2001; 276: 17920-17931. PMID: 11279020
38. Torres-Aguilar H, Aguilar-Ruiz SR, Gonzalez-Perez G, Munguia R, Bajana S, Meraz-Rios MA, et al. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells. J Immunol. 2010; 184: 1765-1775. doi: 10.4049/jimmunol.0902133 PMID: 20083662
39. Moretto MM, Lawlor EM, Khan IA. Lack of interleukin-12 in p40-deficient mice leads to poor CD8+ Tcell immunity against Encephalitozoon cuniculi infection. Infect Immun. 2010; 78: 2505-2511. doi: 10.1128/IAI.00753-09 PMID: 20308292
40. Hilkens CMU, Kalinski P, de Boer M, Kapsenberg ML. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood. 1997; 90: 1920-1926. PMID: 9292525
41. Granucci F, Vizzardelli C, Virzi E, Rescigno M, Ricciardi-Castagnoli P. Transcriptional reprogramming of dendritic cells by differentiation stimuli. Eur J Immunol. 2001; 31: 2539-2546. PMID: 11536151
42. Hegmans JPJJ, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J. 2006; 27: 1086-1095. PMID: 16540497
43. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, et al. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res. 2004; 10: 7260-7269. PMID: 15534100
44. Inoshima N, Nakanishi Y, Minami T, Izumi M, Takayama K, Yoshino I, et al. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res. 2002; 8: 3480-3486. PMID: 12429638
45. Bellone G, Carbone A, Smirne C, Scirelli T, Buffolino A, Novarino A, et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol. 2006; 177: 3448-3460. PMID: 16920987
46. Saito T, Takayama T, Osaki T, Nagai S, Suzuki T, Sato M, et al. Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity. Cancer Sci. 2008; 99: 2028-2036. doi: 10.1111/j.1349-7006.2008.00907.x PMID: 19016763
47. Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest. 2004; 113: 774-783. PMID: 14991076
48. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest. 2007; 117: 1305-1313. PMID: 17415413
49. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999; 5: 2963-2970. PMID: 10537366